At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 356 enrolled
Drug / intervention
AL002 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of AL002 in Participants With Early Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating AL002 and Placebo for Alzheimer Disease. Completed, enrolled 356 participants across 87 sites in 12 countries.
Detailed Summary
A phase 2 randomized, double blind, placebo controlled study evaluating the efficacy and safety of AL002 in participants with Early Alzheimer's Disease.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer Disease
CountriesArgentina, Australia, Canada, France, Germany, Italy, Netherlands, New Zealand, Poland, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartJan 2021
Primary CompletionAug 2024
Study CompletionSep 2024
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartJan 22, 2021
Primary CompletionAug 19, 2024
Study CompletionSep 12, 2024
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 5.7 years ago
Interventions
AL002drug
Administered via intravenous (IV) infusion
Placebodrug
Administered via intravenous (IV) infusion